Aneuploidy in upper gastro-intestinal tract cancers-A potential prognostic marker?

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 651, Issue 1-2, 2008, Pages 93-104

  Doak, Shareen H ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Aneuploidy; Barrett's oesophagus; Gastric cancer; Oesophageal squamous cell carcinoma

Indexed keywords

ADVANCED CANCER; ALCOHOL CONSUMPTION; ANEUPLOIDY; ARTICLE; ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; DNA FRAGMENTATION; DUODENUM ULCER; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRITIS; HIGH RISK PATIENT; HUMAN; INTESTINE METAPLASIA; KARYOTYPE; METASTASIS; NUMERICAL CHROMOSOME ABERRATION; PATIENT CARE; PATIENT CODING; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; SMOKING; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH ULCER; UPPER GASTROINTESTINAL TRACT;

ANEUPLOIDY; ANIMALS; BARRETT ESOPHAGUS; GASTROINTESTINAL NEOPLASMS; HUMANS; MODELS, GENETIC; PROGNOSIS; STOMACH NEOPLASMS;

EID: 43049098968     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2007.10.018     Document Type: Article

References (107)

1. Loeb L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51 (1991) 3075-3079
2. Chung D.C. The genetic basis of colorectal cancer: insights into critical pathways of tumourigenesis. Gastroenterology 119 (2000) 854-865
3. Duesberg P., and Rasnick D. Aneuploidy the somatic mutation that makes cancer a species of its own. Cell Motil. Cytoskeleton 47 (2000) 81-107
4. Bialy H. Aneuploidy and cancer: vintage wine in a new bottle?. Nat. Biotechnol. 16 (1998) 137-138
5. Sen S. Aneuploidy and cancer. Curr. Opin. Oncol. 12 (2000) 82-88
6. Rasnick D. Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. Cancer Genet. Cytogenet. 135 (2002) 66-72
7. Doak S.H., Jenkins G.J.S., Parry E.M., D'Souza F.R., Griffiths A.P., Toffazal N., Shah V., Baxter J.N., and Parry J.M. Chromosome 4 hyperploidy represents an early genetic aberration in premalignant Barrett's oesophagus. Gut 52 (2003) 623-628
8. Greenberg A.K., Yee H., and Rom W.N. Preneoplastic lesions of the lung. Respir. Res. 3 (2002) Article number 20
9. Rabinovitch P.S., Dziadon S., Brentnall T.A., Emond M.J., Crispin D.A., Haggitt R.C., and Bronner M.P. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res. 59 (1999) 5148-5153
10. Williams L., Jenkins G.J.S., Doak S.H., Fowler P., Parry E.M., Brown T.H., Griffiths A.P., Williams J.G., and Parry J.M. Fluorescence in situ hybridisation analysis of chromosomal aberrations in gastric tissue: the potential involvement of Helicobacter pylori. Br. J. Cancer 92 (2005) 1759-1766
11. Parkin D.M., Bray F.I., and Devesa S.S. Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37 (2001) S4-S66
12. Blot W.J., Devesa S.S., Kneller R.W., and Fraumeni J.F. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265 (1991) 1287-1289
13. Devesa S.S., Blot W.J., and Fraumeni J.F. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83 (1998) 2049-2053
14. Pera M., Cameron A.J., Trastek V.F., Carpenter H.A., and Zinsmeister A.R. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104 (1993) 510-513
15. Vizcaino A.P., Moreno V., Lambert R., and Parkin D.M. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int. J. Cancer 99 (2002) 860-868
16. Botterweck A.A.M., Schouten L.J., Volovics A., Dorant E., and van den Brandt P.A. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in then European countries. Int. J. Epidemiol. 29 (2000) 645-654
17. Wang G.-Q., Abnet C.C., Shen Q., Lewin K.L., Sun X.-D., Roth M.J., Qiao Y.-L., Mark S.D., Dong Z.-W., Taylor P.R., and Dawsey S.M. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut 54 (2005) 187-192
18. Corely D.A., and Buffler P.A. Oesophageal and gastric cardia adenocarcniomas: analysis of regional variation using the cancer incidence in five continents database. Int. J. Epidemiol. 30 (2001) 1415-1425
19. Levi F., Randimbison L., Lucchini F., Te V.-C., and La Vecchia C. Epidemiology of adenocarcinoma and squamous cell carcinoma of the oesophagus. Eur. J. Cancer Prev. 10 (2001) 91-96
20. Hansen S., Wiig J.N., Giercksky K.E., and Tretli S. Esophageal and gastric carcinoma in Norway 1958-1992: incidence time trend variability according to morphological subtypes and organ subsites. Int. J. Cancer 71 (1997) 340-344
21. Engel L.S., Chow W.-H., Vaughan T.L., Gammon M.D., Risch H.A., Stanford J.L., Schoenberg J.B., Mayne S.T., Dubrow R., Rotterdam H., West A.B., Blaser M., Blot W.J., Gail M.H., and Fraumeni J.F. Population attributable risks of esophageal and gastric cancers. J. Nat. Cancer. Inst. 95 (2003) 1404-1413
22. Gammon M.D., Schoenberg J.B., Ahsan H., Risch H.A., Vaughan T.L., Chow W.H., Rotterdam H., West A.B., Dubrow R., Stanford J.L., Mayne S.T., Farrow D.C., Niwa S., Blot W.J., and Fraumeni J.F. Tobacco alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Nat. Cancer Inst. 89 (1997) 1277-1284
23. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. The role of tobacco, snuff and alcohol use in the aetiology of cancers of the oesophagus and gastric cardia. Int. J. Cancer 85 (2000) 340-346
24. Terry P., Lagergren J., Hansen H., Wolk A., and Nyren O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur. J. Cancer Prev. 10 (2001) 365-369
25. Hagggit R.C., Tryelaar J., Ellis F.H., and Colcher H. Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Human Pathol. 70 (1978) 1-5
26. Connio M., Cameron A.J., Romero Y., Branch C.D., Schleck C.D., Burgart L.J., Zinsmeister A.R., Melton III L.J., and Locke III G.R. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted Couty, Minnesota. Gut 48 (2001) 304-309
27. O'Conner J.B., Falk G.W., and Richter J.E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus - report on the Cleveland Clinic Barrett's Esophagus Registry. Am. J. Gastroenterol. 94 (1999) 2037-2042
28. Montgomery E., Goldblum J.R., Greenson J.K., Haber M.M., Lamps L.W., Lauwers G.Y., Lazenby A.J., Lewin D.N., Robert M.E., Washington K., Zahurak M.L., and Hart J. Dysplasia as a predictive marker for invasive carcinoma in Barrett's esophagus: a follow up study based on 138 cases from a diagnostic variability study. Human Pathol. 32 (2001) 379-388
29. Reid B.J., Levine D.S., Longton G., Blount P.L., and Rabinovitch P.S. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am. J. Gastroenterol. 95 (2000) 1869-1878
30. Drewitz D.J., Sampliner R.E., and Garewal H.S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am. J. Gastroenterol. 92 (1997) 212-215
31. Nilsson J., Skobe V., Johansson J., Willen R., and Johnsson F. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand. J. Gastrotenterol. 35 (2000) 10-16
32. El-Serag H.B., Mason A.C., Petersen N., and Key C.R. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut 50 (2002) 368-372
33. Hirota W.K., Loughney T.M., Lazas D.J., Maydonovitch C.L., Rholl V., and Wong R.K.H. Specialised intestinal metaplasia, dysplasia and cancer of the oesophagus and oesophagogastric junction: prevalence and clinical data. Gastroenterology 116 (1999) 277-285
34. van Soest E.M., Dieleman J.P., Siersema P.D., Sturkenboom M.C.J.M., and Kuipers E.J. Increasing incidence of Barrett's oesophagus in the general population. Gut 54 (2005) 1062-1066
35. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. New Engl. J. Med. 340 (1999) 825-831
36. Lagergren J., Bergstrom R., and Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann. Int. Med. 130 (1999) 883-890
37. Moe G.L., Kristal A.R., Levine D.S., Vaughan T.L., and Reid B.J. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr. Cancer 36 (2000) 7-13
38. Loffeld R.J.L.F., Werdmuller B.F.M., Kuster J.G., Perez-Perez G.I., Blaser M.J., and Kuipers E.J. Colonization with CagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 62 (2000) 95-99
39. Vaezi M.F., Falk G.W., Peek R.M., Vicari J.J., Goldblum J.R., Perez-Perez G.I., Rice T.W., Blaser M.J., and Richter J.E. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am. J. Gastroenterol. 95 (2000) 2206-2211
40. Kelley J.R., and Duggan J.M. Gastric cancer epidemiology and risk factors. J. Clin. Epidemiol. 56 (2003) 1-9
41. Newnham A., Quinn M.J., Babb P., Kang J.Y., and Majeed A. Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999. Aliment Pharmacol. Ther. 17 (2003) 655-664
42. Helicobacter Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49 (2001) 347-353
43. Correa P. A human model of gastric carcinogenesis. Cancer Res. 48 (1988) 3554-3560
44. Andrejevic Blant S., Ballini J.P., Caron C.T.L., Fontolliet C., Monnier P., and Laurini N.R. Evolution of DNA ploidy during squamous cell carcinogenesis in the esophagus. Dis. Esophagus 14 (2001) 178-184
45. Doki Y., Shiozaki H., Tahara H., Kobayashi K., Miyata M., Oka H., Iihara K., and Mori T. Prognostic value of DNA-ploidy in squamous cell carcinoma of the esophagus - analysed with improved flow cytometric measurement. Cancer 72 (1993) 1813-1818
46. Porschen R., Bevers G., Remy U., Schauseil S., and Borchard F. Influence of preoperative radiotherapy on DNA-ploidy in squamous cell carcinomas of the esophagus. Gut 37 (1993) 1086-1090
47. Robeycafferty S.S., Elnaggar A.K., Sahin A.A., Bruner J.M., Ro J.Y., and Cleary K.R. Prognostic factors in esophageal squamous carcinoma - a study of histologic features, blood-group expression and DNA ploidy. Am. J. Clin. Pathol. 95 (1991) 844-849
48. Watanabe M., Kuwano H., Tanaka S., Toh Y., Sadanaga N., and Sugimachi K. Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the oesophagus. Cancer 85 (1999) 2322-2328
49. Itakura Y., Sasano H., Mori S., and Nagura H. Methods in pathology-DNA-ploidy in human esophageal squamous dysplasias and squamous-cell carcinomas as determined by image-analysis. Mod. Pathol. 7 (1994) 867-873
50. Zuo L.F., Ling P.Z., Qi F.Y., Wang J.X., Ding Z.W., Guo J.W., and Liu J.H. Flow cytometric DNA analyses of epithelial dysplasia of the esophagus. Anal. Quant. Cytol. Histol. 22 (2000) 175-177
51. Mark H.F.L., Rausch M.E., Taylor W.M., Huth A., Mark S., Santoro K., Zolnierz K., Ferreira K., and Barker B.E. Sequential flow cytometry and fluorescence in situ hybridisation for the study of formalin-fixed, paraffin-embedded breast cancer cells. Cancer Genet. Cytogenet. 100 (1998) 129-133
52. Manoel-Caetano F., Borim A.A., Caetano A., Cury P.M., and Silva A.E. Cytogenetic alterations in chagasic achalasia compared to esophageal carcinoma. Cancer Genet. Cytogenet. 149 (2004) 17-22
53. Pack S.D., Karkera J.D., Zhuang Z., Pak E.D., Balan K.V., Hwu P., Park W.-S., Pham T., Ault D.O., Glaser M., Liotta L., Detera-Wadleigh S.D., and Wadleigh R.G. Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridisation reveals a consistent pattern of chromosomal alterations. Genes Chromosome Cancer 25 (1999) 160-168
54. Tada K., Oka M., Tangoku A., Hayashi H., Oga A., and Sasaki K. Gains of 8q23-qter and 20q and loss of 11q22-qter in esophageal squamous cell carcinoma associated with lymph node metastasis. Cancer 88 (2000) 268-273
55. Wei F., Ni J., Wu S.S., Kiu H., Xu X., Han Y.L., Cai Y., Zhang J.W., Chen X.J., Pang H., Ji L., Wu M., and Wang M.R. Cytogenetic studies of esophageal squamous cell carcinomas in the northern Chinese population by comparative genomic hybridization. Cancer Genet. Cytogenet. 138 (2002) 38-43
56. Yamaki H., Sasano H., Ohashi Y., Shizawa S., Shineha R., Satomi S., and Nagura H. Alteration of X and Y chromosomes in human esophageal squamous cell carcinoma. Anticancer Res. 21 (2001) 985-990
57. Reid B.J., Sanchez C.A., Blount P.L., and Levine D.S. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 105 (1993) 119-129
58. Bell S., Li A., Scott N., and Guillou P. Investigation of the genetic events involved in oesophageal carcinoma using comparative genomic hybridisation. J. Med. Genet. 36 (1999) S45
59. Moskaluk C.A., Hu J., and Perlman E.J. Comparative genomic hybridisaiton of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosome Cancer 22 (1998) 305-311
60. van Dekken H., Vissers C.J., Tilanus H.W., Tanke H.J., and Rosenberg C. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridisation. J. Pathol. 188 (1999) 263-266
61. Croft J., Parry E.M., Jenkins G.J.S., Doak S.H., Baxter J.N., Griffiths A.P., Brown T.H., and Parry J.M. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridisation. Eur. J. Gastroenterol. Hepatol. 14 (2002) 1179-1186
62. Riegman P.H.J., Vissers K.J., Alers J.C., Geelen E., Hop W.C.J., Tilanus H.W., and van Dekken H. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res. 61 (2001) 3164-3170
63. Walch A.K., Zitzelsberger H.F., Bruch J., Keller G., Angermeier D., Aubele M.M., Mueller J., Stein H., Braselmann H., Siewert J.R., Hofler H., and Werner M. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am. J. Pathol. 156 (2000) 555-566
64. Beuzen F., Dubois S., and Flejou J.-F. Chromosomal numerical aberrations are frequent in oesophageal and gastric adenocarcinomas: a study using in-situ hybridisation. Histopathology 37 (2000) 241-249
65. Persons D.L., Croughan W.S., Borelli K.A., and Cherian R. Interphase cytogenetics of esophageal adenocarcinoma and precursor lesions. Cancer Genet. Cytogenet. 106 (1998) 11-17
66. Doak S.H., Saidely D., Jenkins G.J.S., Parry E.M., Griffiths A.P., Baxter J.N., and Parry J.M. Generation of locus-specific probes for interphase fluorescence in situ hybridisation - application in Barrett's oesophagus. Exp. Mol. Pathol. 77 (2004) 26-33
67. Fahmy M., Skacel M., Gramlich T.L., Brainard J.A., Rice T.W., Goldblum J.R., Connor J.T., Casey G., Legator M.S., Tubbs R.R., and Falk G.W. Chromosomal gains and genomic loss of p53 and p16 genes in Barrett's esophagus detected by fluorescence in situ hybridisation of cytology specimens. Mod. Pathol. 17 (2004) 588-596
68. Russo A., Bazan V., Migliavacca M., Tubiolo C., Macaluso M., Zanna I., Corsale S., Latteri F., Valerio M.R., Pantuso G., Morello V., Dardanoni G., Latteri M.A., Colucci G., Tomasino R.M., and Gebbia N. DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma-Results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Cancer 92 (2001) 294-302
69. Sasaki O., Kido K., and Nagahama S. DNA ploidy, Ki-67 and p53 as indicators of lymph node metastasis in early gastric carcinoma. Anal. Quant. Cytol. Histol. 21 (1999) 85-88
70. Furuya T., Uchiyama T., Murakami T., Adachi A., Kawauchi S., Oga A., Hirano T., and Sasaki K. Relationship between chromosomal instability and intratumoral regional DNA ploidy heterogeneity in primary gastric cancers. Clin. Cancer Res. 6 (2000) 2815-2820
71. Kim J.Y., and Cho H.J. DNA ploidy patterns in gastric adenocarcinoma. J. Korean Med. Sci. 15 (2000) 159-166
72. Osterheld M.C., Caron L., Dernierre M., Laurini R., and Bosman F.T. DNA-ploidy in advanced gastric carcinoma is less heterogeneous than in early gastric cancer. Cell. Oncol. 26 (2004) 21-29
73. Sugai T., Nakamura S., Uesugi N., Habano W., Yoshida T., Tazawa H., Orii S., Sutto T., and Itoh C. Role of DNA aneuploidy, overexpression of p53 gene product, and cellular proliferation in the progression of gastric cancer. Cytometry 38 (1999) 111-117
74. AbdelWahab M., Attalah A.M., Elshal M.F., Eldousoky I., Zalata K.R., ElGhawalby N.A., ElHak N.G., ElEbidy G., and Ezzat F. Correlation between endoscopy, histopathology, and DNA flow cytometry in patients with gastric dyspepsia. Hepatogastroenterology 43 (1996) 1313-1320
75. Han K., Oh E.J., Kim Y.S., Kim Y.G., Lee K.Y., Kang C.S., Kim B.K., Kim W.I., Shim S.I., and Kim S.M. Chromosomal numerical aberrations in gastric carcinoma: analysis of eighteen cases using in situ hybridisation. Cancer Genet. Cytogenet. 92 (1996) 122-129
76. Kokkola A., Monni O., Puolakkainen P., Larramendy M.L., Victorzon M., Nording S., Haapiainen R., Kivilaakso E., and Knuutila S. 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridisation study. Genes Chromosome Cancer 20 (1997) 38-43
77. Sakakura C., Mori T., Sakabe T., Ariyama Y., Shinomiya T., Date K., Hagiwara A., Yamaguchi T., Takahashi T., Nakamura Y., Abe T., and Inazawa J. Gains, losses and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridisation. Genes Chromosome Cancer 24 (1999) 299-305
78. Yadav M., Hopwood V.L., Multani A.S., Mansfield P.F., Takahashi Y., McIntyre B.W., Udagawa T., and Pathak S. Non-random primary and secondary chromosomal abnormalities in human gastric cancers. Anticancer Res. 16 (1996) 1787-1795
79. Oya M., Yao T., and Tsuneyoshi M. Numerical chromosomal aberration in node-positive early gastric carcinomas: analysis by fluorescence in situ hybridisation and immunohistochemical staining. Int. J. Surg. Pathol. 6 (1998) 189-196
80. Kong G., Oga A., Park C.K., Kawauchi S., Furuya T., and Sasaki K. DNA sequence copy number aberrations associated with histological subtypes and DNA ploidy in gastric carcinoma. Jpn. J. Cancer Res. 92 (2001) 740-747
81. Koo S.H., Kwon K.C., Shin S.Y., Jeon Y.M., Park J.W., Kim S.H., and Noh S.M. Genetic alterations of gastric cancer: comparative genomic hybridisation and fluorescence in situ hybridisation studies. Cancer Genet. Cytogenet. 117 (2000) 97-103
82. Oga A., Kong G., Ishii Y., Izumi H., Park C.Y., and Sasaki K. Preferential loss of 5q14-21 in intestinal-type gastric cancer with DNA aneuploidy. Cytometry 46 (2001) 57-62
83. Li R., Sonik A., Stiondl R., Rasnick D., and Deusberg P. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. PNAS 97 (2000) 3236-3241
84. Cahill D.P., Lengauer C., Yu J., Riggins G.J., Willson J.K.V., Markowitz S.D., Kinzler K.W., and Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 392 (1998) 300-303
85. Myrie K.A., Percy M.J., Azim J.M., Neeley C.K., and Petty E.M. Mutation and expression analysis of human BUB1 and BUBR1 in aneuploid breast cancer cell lines. Cancer Lett. 152 (2000) 193-199
86. Shichiri M., Yoshinaga K., Hisatomi H., Sugihara K., and Hirata Y. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 62 (2002) 13-17
87. Tsukasaki K., Miller C.W., Greenspun E., Eshiaghian S., Kawabata H., Fujimoto T., Tomonaga M., Sawyers C., Said J.W., and Koeffler H.P. Mutations in the mitotic checkpoint gene, MADL1, in human cancers. Oncogene 20 (2001) 3301-3305
88. Lingle W.L., Barrett S.L., Begron V.C., D'Assoro A.B., Boeneman K., Liu W.G., Whitehead C.M., Reynolds C., and Salisbury J.L. Centrosome amplification drives chromosomal instability in breast tumour development. PNAS 99 (2002) 1978-1983
89. Pihan G.A., Purohit A., Wallace J., Knecht H., Woda B., Quesenberry P., and Doxsey S.J. Centrosome defects and genetic instability in malignant tumours. Cancer Res. 58 (1998) 3974-3985
90. Pihan G.A., Purohit A., Wallace J., Malhotra R., Liotta L., and Doxsey S.J. Centrosome defects can account for cellular and genetic changes that characterise prostate cancer progression. Cancer Res. 61 (2001) 2212-2219
91. Doak S.H., Jenkins G.J.S., Parry E.M., Griffiths A.P., Baxter J.N., and Parry J.M. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mut. Res. 547 (2004) 133-144
92. Kamada K., Yamada Y., Hirao T., Fujimoto H., Takahama Y., Ueno M., Takayama T., Naito A., Hirao S., and Nakajima Y. Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol. Rep. 12 (2004) 593-599
93. Tanaka E., Hashimoto Y., Ito T., Okumura T., Kan T., Watanabe G., Imamura M., Inazawa J., and Shimada Y. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin. Cancer Res. 11 (2005) 1827-1834
94. Tong T., Zhong Y.L., Kong J.P., Dong L.J., Song Y.M., Fu M., Liu Z.H., Wang M.R., Guo L.P., Lu S.X., Wu M., and Zhan Q.M. Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin. Cancer Res. 10 (2004) 7304-7310
95. Bischoff J.R., and Plowman G.D. The Aurora/IpI1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9 (1999) 454-459
96. Meraldi P., Honda R., and Nigg E.A. Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells. EMBO J. 21 (2002) 483-492
97. Anand S., Penrhyn-Lowe S., and Venkitaraman A.R. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3 (2003) 51-62
98. Zhou J., Kuang J., Zhong L., Kuo W.L., Gray J.W., Sahin A., Brinkely B.R., and Sen S. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20 (1998) 189-193
99. Michel L.S., Liberal V., Chatterjee A., Kirchwegger R., Pasche B., Gerald W., Dobles M., Sorger P.K., Murty V.V.V.S., and Benezra R. MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature 409 (2001) 355-359
100. Musio A., Montagna C., Zambroni D., Indino E., Barbieri O., Citti L., Villa A., Reid T., and Vezzoni P. Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res. 63 (2003) 2855-2863
101. Wang X., Jin D.-Y., Ng R.W.M., Feng H., Wong Y.C., Cheung A.L.M., and Tsao S.W. Significance of MAD2 expression to mitotic checkpoint control in ovarian cancer cells. Cancer Res. 62 (2002) 1662-1668
102. Imai Y., Shiratori Y., Kato N., Inoue T., and Omata M. Mutational inactivation of mitotic checkpoint genes, hsMAD2 and hBUB1, is rare in sporadic digestive tract cancers. Jpn. J. Cancer Res. 90 (1999) 837-840
103. Shigeishi H., Oue N., Kuniyasu H., Wakikawa A., Yokozaki H., Ishikawa T., and Yasui W. Expression of BUB1 gene correlates with tumour proliferating activity in human gastric carcinomas. Pathobiology 69 (2001) 24-29
104. Kim H.-S., Park K.H., Kim S.A., Wen J., Park S.W., Park B., Gham C.-W., Hyung W.J., Noh S.H., Kim H.K., and Song S.Y. Frequent mutations of human Mad2, but not Bub1 in gastric cancers cause defective mitotic spindle checkpoint. Mut. Res. 578 (2005) 187-201
105. Grabsch H., Takeno S., Parsons W.J., Pomjanski N., Boecking A., Gabbert H.E., and Mueller W. Overexpression of the mitotic checkpoint genes BUB1, BUBR1 and BUB3 in gastric cancer-association with tumour cell proliferation. J. Pathol. 200 (2003) 16-22
106. Tanaka K., Nishioka J., Kato K., Nakmura A., Mouri T., Mili C., Kusunok M., and Nobori T. Mitotic checkpoint protein hsMAD2 as a marker predicting liver metastasis of human gastric cancers. Jpn. J. Cancer Res. 92 (2001) 952-958
107. D'Souza F.R., Jenkins G.J.S., Parry E.M., Baxter J.N., and Parry J.M. Bile acids: do they play a role in Barrett's oesophagus. Gut 52 (2003) A47